Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06530511
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-23
Brief Title:
Polatuzumab Rituximab and Orelabrutinib Combination Regimen PRO in the Treatment of Elderly Frail Patients With Treatment-naive Non-GCB DLBCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Single-arm Multicenter Clinical Study of Polatuzumab Rituximab and Orelabrutinib Combination Regimen PRO in the Treatment of Elderly Patients With Frail Treatment-naive Non-germinal Center Subtype Diffuse Large B-cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective single-arm multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab Rituximab and orelabrutinib in this population The primary endpoint is CR rate after induction therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None